Ocaratuzumab is used for the treatment of cancer and autoimmune disorders. The antibody has been designed with an increased affinity to the CD20 antigen on B-lymphocytes, to enhance antibody-dependent cell-mediated cytotoxicity (ADCC).
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Send us a message from the form below
Lab / Company